PPARγ-coactivator-1α gene transfer reduces neuronal loss and amyloid-β generation by reducing β-secretase in an Alzheimer's disease model

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 43, 2016, Pages 12292-12297

  Katsouri, Loukia ^a   Lim, Yau M ^a   Blondrath, Katrin ^a   Eleftheriadou, Ioanna ^a   Lombardero, Laura ^a   Birch, Amy M ^a   Mirzaei, Nazanin ^a   Irvine, Elaine E ^b   Mazarakis, Nicholas D ^a   Sastre, Magdalena ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

A ; BACE1; Growth factor; Inflammation; Neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LENTIVIRUS VECTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEURON SPECIFIC NUCLEAR PROTEIN; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; POSTSYNAPTIC DENSITY PROTEIN 95; TUMOR NECROSIS FACTOR; ASPARTIC PROTEINASE; BACE1 PROTEIN, MOUSE; PPARGC1A PROTEIN, HUMAN; SECRETASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN CORTEX; BRAIN NERVE CELL; CARBOXY TERMINAL SEQUENCE; CELL ACTIVATION; CELL LOSS; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GENE EXPRESSION; GENE OVEREXPRESSION; HIPPOCAMPAL CA3 REGION; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROTROPISM; NONHUMAN; PARIETAL CORTEX; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PYRAMIDAL NERVE CELL; SPATIAL MEMORY; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; HUMAN; LENTIVIRUS; MEMORY; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEINOSIS; THERAPEUTIC USE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; LENTIVIRUS; MEMORY; MICE, TRANSGENIC; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; PROTEIN AGGREGATION, PATHOLOGICAL; PYRAMIDAL CELLS;

EID: 84992378402     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1606171113     Document Type: Article

References (42)

1. Prince M, et al. (2015) World Alzheimer Report 2015, The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. [Alzheimer's Disease International (ADI), London].
2. Galimberti D, Scarpini E (2011) Alzheimer's disease: From pathogenesis to diseasemodifying approaches. CNS Neurol Disord Drug Targets 10(2):163-174.
3. Vassar R (2014) BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther 6(9):89.
4. Puigserver P, Spiegelman BM (2003) Peroxisome proliferator-activated receptorgamma coactivator 1 alpha (PGC-1 alpha): Transcriptional coactivator and metabolic regulator. Endocr Rev 24(1):78-90.
5. Austin S, St-Pierre J (2012) PGC1α and mitochondrial metabolism-emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci 125(Pt 21):4963-4971.
6. Katsouri L, Blondrath K, Sastre M (2012) Peroxisome proliferator-activated receptor-γ cofactors in neurodegeneration. IUBMB Life 64(12):958-964.
7. Katsouri L, Parr C, Bogdanovic N, Willem M, Sastre M (2011) PPARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism. J Alzheimers Dis 25(1):151-162.
8. Qin W, et al. (2009) PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol 66(3):352-361.
9. Gong B, et al. (2013) Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging 34(6):1581-1588.
10. Karuppagounder SS, et al. (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 54(2):111-118.
11. Mazarakis ND, et al. (2001) Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 10(19):2109-2121.
12. Sturchler-Pierrat C, et al. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94(24):13287-13292.
13. Bondolfi L, et al. (2002) Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci 22(2):515-522.
14. Katsouri L, et al. (2013) Prazosin, an α (1)-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease. Neurobiol Aging 34(4):1105-1115.
15. Youmans KL, et al. (2012) Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody. Mol Neurodegener 7(1):8.
16. Calhoun ME, et al. (1998) Neuron loss in APP transgenic mice. Nature 395(6704):755-756.
17. Tuszynski MH, et al. (2015) Nerve growth factor gene therapy: Activation of neuronal responses in Alzheimer disease. JAMA Neurol 72(10):1139-1147.
18. Aloe L, Rocco ML, Bianchi P, Manni L (2012) Nerve growth factor: From the early discoveries to the potential clinical use. J Transl Med 10(1):239.
19. Nagahara AH, et al. (2013) Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci 33(39):15596-15602.
20. Wrann CD, et al. (2013) Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab 18(5):649-659.
21. Kariharan T, et al. (2015) Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression. Neurobiol Aging 36(3):1451-1461.
22. Roy A, et al. (2015) HMG-CoA reductase inhibitors bind to PPARα to upregulate neurotrophin expression in the brain and improve memory in mice. Cell Metab 22(2):253-265.
23. Leone TC, et al. (2005) PGC-1alpha deficiency causes multi-system energy metabolic derangements: Muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 3(4):e101.
24. Lin J, et al. (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119(1):121-135.
25. Sastre M, et al. (2006) Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA 103(2):443-448.
26. Tsunemi T, et al. (2012) PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med 4(142):142ra97.
27. Dumont M, et al. (2014) PGC-1α overexpression exacerbates β-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease. FASEB J 28(4):1745-1755.
28. Miura S, et al. (2006) Overexpression of peroxisome proliferator-activated receptor γ co-activator-1α leads to muscle atrophy with depletion of ATP. Am J Pathol 169(4):1129-1139.
29. Russell LK, et al. (2004) Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 94(4):525-533.
30. Ciron C, Lengacher S, Dusonchet J, Aebischer P, Schneider BL (2012) Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function. Hum Mol Genet 21(8):1861-1876.
31. Clark J, et al. (2012) Pgc-1α overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf. PLoS One 7(11):e48925.
32. Cui L, et al. (2006) Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127(1):59-69.
33. St-Pierre J, et al. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127(2):397-408.
34. Ralph GS, et al. (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 11(4):429-433.
35. Azzouz M, et al. (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429(6990):413-417.
36. Azzouz M, et al. (2004) Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 114(12):1726-1731.
37. Wong L-F, et al. (2006) Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord. Nat Neurosci 9(2):243-250.
38. Palfi S, et al. (2014) Long-term safety and tolerability of ProSavin, a lentiviral vectorbased gene therapy for Parkinson's disease: A dose escalation, open-label, phase 1/2 trial. Lancet 383(9923):1138-1146.
39. Eleftheriadou I, Trabalza A, Ellison S, Gharun K, Mazarakis N (2014) Specific retrograde transduction of spinal motor neurons using lentiviral vectors targeted to presynaptic NMJ receptors. Mol Ther 22(7):1285-1298.
40. Assini FL, Duzzioni M, Takahashi RN (2009) Object location memory in mice: Pharmacological validation and further evidence of hippocampal CA1 participation. Behav Brain Res 204(1):206-211.
41. Hammond RS, Tull LE, Stackman RW (2004) On the delay-dependent involvement of the hippocampus in object recognition memory. Neurobiol Learn Mem 82(1):26-34.
42. Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW (2014) Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition. J Neuroinflammation 11(1):111.